A systematic evaluation of poloxamers as tablet lubricants.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Feb 2020
Historique:
received: 19 10 2019
revised: 18 12 2019
accepted: 22 12 2019
pubmed: 2 1 2020
medline: 18 11 2020
entrez: 2 1 2020
Statut: ppublish

Résumé

Lubricants are important for both preserving the tooling of high-speed tablet presses and attaining quality tablets. Magnesium stearate (MgSt) is most commonly used due to its superior lubrication efficiency; however, it can lead to negative effects on tabletability and dissolution. In this study, we have systematically evaluated two poloxamers, P188 and P407, for their suitability as alternative tablet lubricants. For two excipients with different mechanical properties, i.e., microcrystalline cellulose and lactose, both poloxamers exhibit acceptable lubrication efficiency without negatively impacting tabletability. Compared to 1% MgSt, the performance of 2% of both poloxamers in an experimental tablet formulation of ritonavir led to better lubrication, higher tabletability, and enhanced in vitro drug release. Thus, the use of P188 and P407 as alternative tablet lubricants deserves further evaluations.

Identifiants

pubmed: 31893543
pii: S0378-5173(19)31055-5
doi: 10.1016/j.ijpharm.2019.118994
pii:
doi:

Substances chimiques

Excipients 0
Lubricants 0
Stearic Acids 0
Tablets 0
Poloxamer 106392-12-5
stearic acid 4ELV7Z65AP
Cellulose 9004-34-6
Lactose J2B2A4N98G
Ritonavir O3J8G9O825
microcrystalline cellulose OP1R32D61U

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118994

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jiangnan Dun (J)

Pharmaceutical Materials Science and Engineering Laboratory, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 9-127B Weaver-Densford Hall, 308 Harvard Street S.E., Minneapolis, MN 55455, United States.

Frederick Osei-Yeboah (F)

Product and Technical Development, Biogen, 225 Binney St., Cambridge, MA 02142, United States.

Pierre Boulas (P)

Product and Technical Development, Biogen, 225 Binney St., Cambridge, MA 02142, United States.

Yiqing Lin (Y)

Product and Technical Development, Biogen, 225 Binney St., Cambridge, MA 02142, United States. Electronic address: yiqing.lin@biogen.com.

Changquan Calvin Sun (CC)

Pharmaceutical Materials Science and Engineering Laboratory, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 9-127B Weaver-Densford Hall, 308 Harvard Street S.E., Minneapolis, MN 55455, United States. Electronic address: unx0053@umn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Animals Rumen Methane Fermentation Cannabis
Inclusion Bodies Solubility Recombinant Proteins Detergents Protein Denaturation

Classifications MeSH